AstraZeneca Scraps Volrustomig Lung Trial as Enhertu Data Offsets Pipeline Setback
The FTSE-listed pharmaceutical group discontinued a late-stage lung cancer study of its bispecific candidate after a data setback, even as Enhertu delivered a progression-free survival benefit in a separate lung indication — leaving the stock higher on the day.
AstraZeneca discontinued a Phase 3 trial of volrustomig in lung cancer following disappointing data, a meaningful blow to its next-generation immuno-oncology ambitions. The negative headline was cushioned by positive progression-free survival results for Enhertu in a lung cancer setting, and shares traded higher as investors weighted the commercial-stage readout more heavily than the pipeline write-down.